Idh Mutant | List of Frontiers open access articles

Original Research

Published on 22 Oct 2020

Hypermethylation of LATS2 Promoter and Its Prognostic Value in IDH-Mutated Low-Grade Gliomas

in Signaling

Yuan Gu
Yu Wang
Yebin Wang
Jiaqian Luo
Xin Wang
Mingyue Ma
Wei Hua
Ying Liu
Fa-Xing Yu

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2020.586581

4,961 views
10 citations

Original Research

Published on 04 Dec 2023

The involvement of brain regions associated with lower KPS and shorter survival time predicts a poor prognosis in glioma

in Neuro-Oncology and Neurosurgical Oncology

Hongbo Bao
Huan Wang
Qian Sun
Yujie Wang
Hui Liu
Peng Liang
Zhonghua Lv

Frontiers in Neurology

doi 10.3389/fneur.2023.1264322

3,200 views
9 citations

Mini Review

Published on 21 Jan 2021

Genetic Architectures and Cell-of-Origin in Glioblastoma

in Neuro-Oncology and Neurosurgical Oncology

Hyun Jung Kim
Jung Won Park
Jeong Ho Lee

Frontiers in Oncology

doi 10.3389/fonc.2020.615400

18,861 views
64 citations

Review

Published on 13 Jun 2022

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma

in Cancer Immunity and Immunotherapy

Dongming Yan
Weicheng Li
Qibing Liu
Kun Yang

Frontiers in Immunology

doi 10.3389/fimmu.2022.914618

8,820 views
25 citations

Mini Review

Published on 27 Jun 2025

Vorasidenib for IDH-mutant grade 2 gliomas: clinical advances and future directions

in Neuro-Oncology and Neurosurgical Oncology

Zhenjiang Pan
Jing Bao
Shepeng Wei

Frontiers in Oncology

doi 10.3389/fonc.2025.1628195

7,534 views
3 citations

Original Research

Published on 04 Feb 2021

CyTOF Analysis Reveals a Distinct Immunosuppressive Microenvironment in IDH Mutant Anaplastic Gliomas

in Molecular and Cellular Oncology

Weilun Fu
Wenjing Wang
Hao Li
Yuming Jiao
Jiancong Weng
Ran Huo
Zihan Yan
Jie Wang
Hongyuan Xu
Shuo Wang

Frontiers in Oncology

doi 10.3389/fonc.2020.560211

5,808 views
8 citations

Case Report

Published on 08 Jul 2025

Case Report: Improved hearing in a rare, adult IDH2-mutant brainstem astrocytoma successfully treated with radiation and temozolomide

in Neuro-Oncology and Neurosurgical Oncology

Takuya Okada
Manabu Natsumeda
Hidemoto Fujiwara
Nayuta Higa
Toshiaki Akahane
Yuki Watabe
Kaoru Tomikawa
Kyoka Nishita
Yoshihiro Tsukamoto
Shinsuke Ohshima

Frontiers in Oncology

doi 10.3389/fonc.2025.1555986

2,924 views
1 citation

Original Research

Published on 18 Nov 2025

How to predict progression-free survival in patients with grade 2 IDH-mutated diffuse gliomas after surgery: a long-term follow-up analysis

in Neuro-Oncology and Neurosurgical Oncology

Marta Aprile
Vincenzo Di Nunno
Lidia Gatto
Alicia Tosoni
Damiano Balestrini
Vania Ramponi
Alfredo Conti
Monica Maffei
Stella Battaglia
Chiara Maria Argento

Frontiers in Oncology

doi 10.3389/fonc.2025.1673285

2,283 views

Case Report

Published on 26 Sep 2025

A case report on IDH-mutant astrocytoma, CNS WHO grade 4: multi-omic characterization of untreated clinical progression

in Neuro-Oncology and Neurosurgical Oncology

Xiaoqin Tang
Wei Wei
Yanyan Huang
Yi Zheng
Yajing Xu
Fei Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1557245

3,156 views
1 citation

Case Report

Published on 30 Jan 2025

Case report: Pseudoprogression mimicking neoplastic recurrence three months after completion of proton beam therapy for an IDH-mutant astrocytoma CNS WHO grade 3

in Radiation Oncology

Liv Cathrine Heggebø
Ida Maria Henriksen Borgen
Hanne Blakstad
Cathrine Saxhaug
Pål André Rønning
Pitt Frederik Niehusmann
Katja Werlenius
Malin Blomstrand
Petter Brandal

Frontiers in Oncology

doi 10.3389/fonc.2025.1397912

2,533 views
1 citation

Review

Published on 20 Mar 2024

High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma

in Neuro-Oncology and Neurosurgical Oncology

Johannes Pöhlmann
Michael Weller
Andrea Marcellusi
Kristin Grabe-Heyne
Lucia Krott-Coi
Silvia Rabar
Richard F. Pollock

Frontiers in Oncology

doi 10.3389/fonc.2024.1368606

14,781 views
30 citations

Original Research

Published on 26 Feb 2024

Clinical roles of EGFR amplification in diffuse gliomas: a real-world study using the 2021 WHO classification of CNS tumors

in Translational Neuroscience

Hai Wang
Xin Zhang
Jiahui Liu
Wenlin Chen
Xiaopeng Guo
Yaning Wang
Yuekun Wang
Hao Xing
Tingyu Liang
Yixin Shi

Frontiers in Neuroscience

doi 10.3389/fnins.2024.1308627

7,338 views
17 citations

Perspective

Published on 06 Jan 2025

IDH-mutant gliomas in children and adolescents - from biology to clinical trials

in Pediatric Oncology

Louise Evans
Sarah Trinder
Andrew Dodgshun
David D. Eisenstat
James R. Whittle
Jordan R. Hansford
Santosh Valvi

Frontiers in Oncology

doi 10.3389/fonc.2024.1515538

5,954 views
6 citations

Original Research

Published on 18 Aug 2020

Frequency and Prognostic Value of IDH Mutations in Korean Patients With Cholangiocarcinoma

in Gastrointestinal Cancers

Nah Ihm Kim
Myung-Giun Noh
Jo-Heon Kim
Eun Jeong Won
Yu Jeong Lee
Younghoe Hur
Kyung-Sub Moon
Kyung-Hwa Lee
Jae-Hyuk Lee

Frontiers in Oncology

doi 10.3389/fonc.2020.01514

5,376 views
15 citations

Review

Published on 23 Jun 2022

The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia

in Hematologic Malignancies

Xiaomei Zhuang
Han Zhong Pei
Tianwen Li
Junbin Huang
Yao Guo
Yuming Zhao
Ming Yang
Dengyang Zhang
Zhiguang Chang
Qi Zhang

Frontiers in Oncology

doi 10.3389/fonc.2022.931462

10,709 views
35 citations

Case Report

Published on 17 Aug 2023

Constitutional mismatch repair deficiency syndrome with atypical features caused by a homozygous MLH1 missense variant (c.1918C>A, p.(Pro640Thr)): a case report

in Cancer Genetics

Firas Akrout
Ahlem Achour
Carli M. J. Tops
Richard Gallon
Rym Meddeb
Sameh Achoura
Mariem Ben Rekaya
Emna Hamdeni
Soumaya Rammeh
Ridha Chkili

Frontiers in Oncology

doi 10.3389/fonc.2023.1195814

4,290 views
2 citations

Articles

Hypermethylation of LATS2 Promoter and Its Prognostic Value in IDH-Mutated Low-Grade Gliomas

The involvement of brain regions associated with lower KPS and shorter survival time predicts a poor prognosis in glioma

Genetic Architectures and Cell-of-Origin in Glioblastoma

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma

Vorasidenib for IDH-mutant grade 2 gliomas: clinical advances and future directions

CyTOF Analysis Reveals a Distinct Immunosuppressive Microenvironment in IDH Mutant Anaplastic Gliomas

Case Report: Improved hearing in a rare, adult IDH2-mutant brainstem astrocytoma successfully treated with radiation and temozolomide

How to predict progression-free survival in patients with grade 2 IDH-mutated diffuse gliomas after surgery: a long-term follow-up analysis

A case report on IDH-mutant astrocytoma, CNS WHO grade 4: multi-omic characterization of untreated clinical progression

Case report: Pseudoprogression mimicking neoplastic recurrence three months after completion of proton beam therapy for an IDH-mutant astrocytoma CNS WHO grade 3

High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma

Clinical roles of EGFR amplification in diffuse gliomas: a real-world study using the 2021 WHO classification of CNS tumors

IDH-mutant gliomas in children and adolescents - from biology to clinical trials

Frequency and Prognostic Value of IDH Mutations in Korean Patients With Cholangiocarcinoma

The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia

Constitutional mismatch repair deficiency syndrome with atypical features caused by a homozygous MLH1 missense variant (c.1918C>A, p.(Pro640Thr)): a case report